The Investor Relations website contains information about Cassava Sciences, Inc.'s business for stockholders, potential investors, and financial analysts.| Cassava Sciences, Inc.
The Investor Relations website contains information about Cassava Sciences, Inc.'s business for stockholders, potential investors, and financial analysts.| Cassava Sciences, Inc.
The Investor Relations website contains information about Cassava Sciences, Inc.'s business for stockholders, potential investors, and financial analysts.| Cassava Sciences, Inc.
The Investor Relations website contains information about Cassava Sciences, Inc.'s business for stockholders, potential investors, and financial analysts.| Cassava Sciences, Inc.
Simufilam, a small molecule targeting the filamin A protein, is being tested in clinical trials to potentially treat Alzheimer's disease.| Alzheimer's News Today
Nearly half of some 200 mild-to-moderate Alzheimer’s patients treated with oral simufilam for one year showed gains in cognitive tests.| Alzheimer's News Today
Columnist Ray Burow now understands that those who get an Alzheimer's diagnosis need time to come to grips with the disease.| Alzheimer's News Today
Category archive page for Columns.| Alzheimer's News Today
Learn more about Alzheimer's disease, the most common cause of dementia and an irreversible, progressive neurological disorder.| Alzheimer's News Today
